Research Article

Genetic Polymorphisms in miR-137 and Its Target Genes, TCF4 and CACNA1C, Contribute to the Risk of Bipolar Disorder: A Preliminary Case-Control Study and Bioinformatics Analysis

Mohammad Ali Mokhtari,1 Saman Sargazi ,2 Ramin Saravani ,1,2 Milad Heidari Nia ,1,2 Shekoufeh Mirinejad ,2 Kinga Hadzsiev ,3 Judit Bene ,3 and Mansoor Shakiba4

1Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan 98167-43463, Iran
2Cellular and Molecular Research Center, Research Institute of Cellular and Molecular Sciences in Infectious Diseases, Zahedan University of Medical Sciences, Zahedan 98167-43463, Iran
3Department of Medical Genetics, Clinical Center, Medical School, University of Pécs, Pécs H-7624, Hungary
4Department of Psychiatry, Zahedan University of Medical Sciences, Zahedan 98167-43463, Iran

Correspondence should be addressed to Ramin Saravani; saravaniramin@yahoo.com

Received 4 May 2022; Accepted 2 September 2022; Published 22 September 2022

Academic Editor: Atif Amin Baig

Copyright © 2022 Mohammad Ali Mokhtari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Accumulating evidence has suggested that miR-137 and its target genes, CACNA1C, and TCF4, are amongst the most robustly implicated genes in psychiatric disorders. This preliminary study is aimed at investigating the effects of genetic variations in miR-137 (rs1625579A/C), TCF4 (rs1261084C/T), and CACNA1C (rs10774053A/G and rs10466907G/T) on BD susceptibility. We recruited 252 BD patients and 213 healthy subjects as the control group. Genotyping was performed using PCR-RFLP and ARMS-PCR methods. Enhanced risk of BD was found under the codominant homozygous, dominant, and allelic models of TCF4 rs1261084C/T, codominant homozygous and allelic models of CACNA1C rs10466907G/T polymorphisms, as well as codominant homozygous, dominant, recessive, and allelic models of the CACNA1C rs10774053A/G. Moreover, both TT/AG/GT/AA and TT/GG/GT/AC genotype combinations strongly increased the risk of BD in the participants. The bioinformatics analyses revealed that rs1261084C/T and rs10466907G/T created and disrupted binding sites of some miRNAs in the 3′-untranslated region of TCF4 and CACNA1C genes. In contrast, the rs10774053A/G created a new binding site for a major splicing factor and might have an effective role in the function of the CACNA1C protein. We have found that all the studied SNPs are positively associated with BD susceptibility. Replicated studies on different ethnicities are required to confirm these findings.

1. Introduction

Bipolar disorder (BD), also known as manic depression, is a severe mood disorder characterized by recurrent episodes of mania, depression, and abnormally elevated mood, which affect thought, perception, emotion, and social behavior [1]. Challenges like suicidal behavior, family devastation, psychological problems, and hospitalization have made BD a significant public health concern [2]. Most studies have reported 12-month estimates of approximately 1% for BD in European countries [3]. The Global Burden of Disease Study 2013 (GBD 2013) estimated 32.7 million cases of BD in 1990. However, by 2013, that number had increased to 48.8 million, a 49.1 percent rise in BD prevalence due to population growth and aging [4]. Results from the Global Burden of Disease Study 2017 showed that the disability-adjusted life years (DALYs) surged by 54.4 percent in BD patients, from 6.02 million in 1990 to 9.29 million in 2017. With age-standardized incidence rate (ASIR) and age-standardized DALYs rate (ASDR) being lowest in East Asia and highest in tropical Latin America [5]. An epidemiological survey of psychiatric disorders in 2005 reported that the
prevalence rate of bipolar mood disorder (BMD) was 0.96% in Iranians. Also, the prevalence of mood disorders was found to be 4.29%, with major depressive disorder (2.98%) having the highest incidence among mood disorders [6]. Still, for many parts of the world, including Iran, there has been limited or no prevalence data available [7].

Generally, BD is categorized into two subtypes: type I of BD (BDI) BDI and type II of BD (BDII) BDII. Patients with BDI experience at least one episode of mania or depression. In addition, they can also experience hypomanic and mixed episodes. Patients with BDII, on the other hand, mostly present hypomania and major depressive episodes. [8]. Growing evidence implies that some genetics and environmental factors influence the risk of BD, making it a multifactorial disease [9]. The precise etiology of BD has remained unclear; however, twins and adopted are exposed to a higher incidence for BD development [10]. More importantly, family history is among the most substantial risk factors affecting susceptibility to BD and implies crucial genetic and phenotypic complexity [11].

Meta-analysis of BD genome-wide association studies (GWASs) has discovered that many single nucleotide polymorphisms (SNPs) are associated with an enhanced risk of this mental disorder [12–14]. However, until 2013, these variations accounted for little inherited risk in Europeans [15]. Following the first GWAS of BD in 2007, several loci, including NCAN, ANK3, and CACNA1C, were found to be associated with BD risk, and these findings were later confirmed by some population-based genetic association studies [11, 13, 16].

Increasing evidence has shown that noncoding RNAs (ncRNAs), like microRNAs (miRNAs), are likely to contribute to the etiology of psychiatric disorders, such as BD [17]. In this respect, differential expression of some miRNAs has been detected in prefrontal regions of patients with schizophrenia (SCZ) or BD as compared to healthy individuals [18, 19]. Reports have already established that SCZ and BD share some overlapping genetic factors and abnormalities in the structure and function of the brain [20, 21]. Moreover, BD tends to resemble SCZ from the prospect of several genetic variations with low minor allele frequencies (MAFs) [22].

miRNAs are a broad subgroup of small ncRNAs that regulate gene expression through posttranscriptional mechanisms [23]. The nervous system has the broadest miRNA expression profile among all human tissues, with the most well-known miRNAs expressed in the neurons [24]. Some evidence suggests that miRNAs regulate the human brain’s function and development [25]. Different studies have reported dysregulation of miRNAs in brain samples of BD patients [26–28].

miR-137, as an abundant microRNA in the brain, is crucial for controlling synaptic development, neuronal proliferation and differentiation, and the fates of embryonic neural stem cells (NSCs). As a result of its dysregulation, the neurological system’s network that controls gene expression is altered, leading to mental illnesses [29]. miR-137 is highly expressed in synapses in the cortex and hippocampus of adult humans [30, 31]. It has been established that the upregulation of miR-137 in the dentate gyrus of patients with SCZ or BD [31]. Hence, normal expression of miR-137 is required for modulating neuronal proliferation and differentiation [32]. Some of the putative miR-137 target genes, such as CUB and Sushi multiple domains 1 (CSMD1), C10orf26 [now WBP1L], transcription factor 4 (TCF4), Zinc Finger Protein 804A (ZNF804A), and αc-subunit of the L-type calcium channel (CACNA1C), have also shown significant correlation with BD. These genes have been confirmed as miR-137 targets by in vitro methods [33]. In addition, gene sets of possible miR-137 targets, including target sets implicated in axonal guidance signaling, Ephrin receptor signaling, long-term potentiation, PKA signaling, and Sertoli cell junction signaling, were enriched with variations associated with the risk of psychiatric diseases, such as SCZ [34]. Recent evidence has suggested the extensive polygenic overlap between risk phenotypes and BD and SCZ. In this connection, identifying specific loci associating with this shared risk helps understand physiologically feasible pathways that may explain risk-taking in patients with severe psychiatric disorders [35]. Because of this shared genetic backgrounds, miR-137 may also serve as a new player in BD. Therefore, the role of this miRNA and its downstream genes in regulating networks involved in neural development and brain function of BD patients is worth investigating.

Mainly, CACNA1C has been introduced by GWASs as a risk factor for the onset and development of BD [17, 36]. The CACNA1C gene encodes the α subunit of the voltage-dependent L-type calcium channel Cav1.2 protein [37]. Many recent reports have been published on the association between CACNA1C SNPs and behavior, neurogenesis, and risk of psychiatric disorders such as SCZ, BD, and depression. Their findings suggested a common genetic profile among them [17, 38, 39]. Therefore, CACNA1C genetic variations have ranked among the most conclusive genetic findings in such disorders [40]. On the other hand, the TCF4 gene encodes a transcription factor involved in developing a subset of neuronal progenitors. It has been shown that TCF4 overexpression resulted in SCZ-associated behaviors in transgenic mice [41, 42].

We have previously shown that various SNPs located in candidate genes could interact with adverse life events and greatly influence the risk of developing psychiatric disorders [43–47], including BD [48]. In the current study, for the first time, we aimed to evaluate the association between SNPs located within miR-137 (rs1625579A/C) and its target genes TCF4 (rs1261084C/T) and CACNA1C (rs10774053A/G and rs10466907G/T) and the risk of BD in an Iranian population.

2. Materials and Methods

2.1. Participants and Sample Collection. This case-control study was conducted on 252 subjects with BD referred to Baharan psychiatry hospital, Zahedan, Iran. The control group comprised 213 unrelated healthy subjects recruited by general advertisement through local community groups. These subjects have no family history of neuropsychiatric...
disorders or drug abuse. A clinical interview was used to exclude potential controls with BD based on criteria provided by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V). Diagnosis of BD patients was made according to the diagnostic criteria provided in DSM-V as per the structured clinical interview [49, 50]. Two board-certified psychiatrists carefully examined these cases. Patients diagnosed with major depressive disorder, cyclothymic disorder, SCZ spectrum disorder, panic disorder, anxiety disorder, borderline personality disorder, substance use disorder, attention-deficit/hyperactivity disorder (ADHD), and related neuropsychiatric disorder were excluded. All subjects were adjusted regarding age, gender, and body mass index (BMI).

2.2. DNA Extraction and Genotyping. About 5 mL of the peripheral blood sample was drawn from all subjects in both case and control groups and collected into ethylenediaminetetraacetic acid- (EDTA-) contained tubes. DNA extraction was carried out using the salting-out method [51]. The restriction fragment length polymorphism-polymerase chain reaction (RFLP-PCR) technique [52] was used for genotyping both rs1261084C/T and rs10774053A/G SNPs. In addition, an amplification-refractory mutation system polymerase chain reaction (ARMS-PCR) [53] was applied to detect rs10466907G/T and rs1625579A/C variants. Information regarding the primer’s sequences [designed via GeneRunner program (available from http://www.generunner.net/)] and the size of products are shown in Table 1.

For detecting all studied SNPs, the PCR reaction was performed with the predenaturation step at 95°C for 5 min, 35 cycles of denaturation at 95°C for 30 s, annealing at an appropriate temperature (based on Table 1) for 30 s, an extension at 72°C for 30 s, followed by a final extension step at 72°C for 5 min. The reaction tubes contained 10 μL of Taq DNA polymerase 2× Master Mix (Pars Tous Biotech Company, Iran), 0.7 μL of each primer (10 pm/μL) (GenFanaVaran Biotech company, Iran), 0.6 μL of genomic DNA, and 8 μL of deionized water, reaching a final volume of 20 μL. For detection of rs1261084C/T, 10 μL of the PCR product was incubated with 1 μL of the FokI restriction enzyme (10 U/μL, Fermentas, Germany) and 2 μL of a 10× CutsMart buffer (in a total 20 μL reaction) overnight at 37°C. As for rs10774053A/G, 10 μL of PCR product of was digested by 1 μL of MspI (10 U/μL, Fermentas, Germany) restriction enzyme and incubated with 9 μL of 10× Buffer Tango at 37°C for 16 hours, with the same reaction volume. The final fragments were separated through electrophoresis in 2% agarose gels stained with DNA Green Viewer (Pars Tous, Company, Iran) and visualized using an ultraviolet light system (Figure 1). For quality control, approximately 25% of the samples were randomly genotyped, and genotyping accuracy was 100%.

2.3. Statistical Analysis. Data were analyzed using the SPSS package for windows, V22.0 (IBM Corporation, Armonk, NY, USA). To calculate the sample size, we first performed a pilot study by collecting the blood samples of a small population (100 subjects, including 50 BD patients and 50 healthy subjects) and genotyping the four SNPs. Next, the allelic frequencies of the SNPs in both groups were determined using the Chi-square test. The calculated frequencies were then analyzed using an online sample size calculator server (available at: https://clincalc.com/stats/SampleSize.aspx) [54]. The server uses the following formula for calculating sample size.

\[
n = \frac{(z_{1-\alpha/2} + z_{1-\beta})^2 (P_1 (1-P_1) + P_2 (1-P_2))}{(P_1 - P_2)^2},
\]

where, 

- \( P_1 \) represents the frequency of the wild or mutant allele in control,
- \( P_2 \) is the frequency of the wild or mutant allele in case,
- \( Z \) is the critical Z value for a given \( \alpha \) or \( \beta \), \( \alpha \) indicates the probability of type I error (usually 0.05), and \( \beta \) is considered the probability of type II error (usually 0.2).

With study power set to 80%, the sample size was calculated for the tested SNPs in studied groups via the calculator. The threshold of sample size was then adjusted to a total of 465 subjects. Deviations from HWE in cases and controls were examined using the Chi-square (\( \chi^2 \)). Quantitative data were reported as the mean and standard deviation and expressed as numbers and/or percentages. Statistical differences between data sets were analyzed using multivariate logistic regression, the independent \( t \)-test, or the Mann–Whitney test, where appropriate. The \( \chi^2 \) test was also used to calculate differences between the genotypic and allelic frequencies of the subjects in the studied population. The odds ratios (ORs) and the 95% confidence intervals (CIs) were similarly measured. A \( p \) value <0.05 was considered statistically significant.

2.4. Computational Analyses. Computational analyses were performed to investigate the impact of studied SNPs on the different aspects, including secondary structure of transcripts, miRNA binding sites, splicing sites, and protein function. For this purpose, the mirSNP database, as a collection of human SNPs in predicted miRNA target sites, was used to detect the effect of SNPs on the miRNA binding sites [55]. The SpliceAid2 database was recruited to determine the effects of allele substitutions on the binding site of transcriptional regulators and splicing factors [56]. Using protein information, the SNAP server predicts the effect of non-synonymous SNPs on protein function [57]. The miRWayDB database was utilized to experimentally validate miRNA pathway associations under pathophysiological conditions [58].

3. Results

3.1. Clinical and Demographic Characteristics of the Studied Subjects. Table 2 summarizes the clinical and demographic characteristics of BD patients and controls. No statistical differences were observed between the studied groups regarding age, gender, and BMI (\( P = 0.326 \), \( P = 0.899 \), and \( P = 0.745 \), respectively). The average age of BD onset was about 25.96 ± 9.71 years in our population. Approximately
183 (72.6%) patients were diagnosed with BDI, and the others were diagnosed with BDII (27.4%). There were no significant differences in age or gender between the BDI and BDII subgroups ($P = 0.062$ and 0.823, respectively). In addition, most patients were unemployed (59.1%) and had experienced mania (47.2%) at the time of diagnosis. About 34.1% of BD subjects presented with depression, and 18.7% simultaneously experienced mania and depression. Moreover, we found that 64.3% of BD patients had a family history of mood disorders in their first-degree relatives. We did not find any difference in the family history of mood disorders between the BDI and BDII subgroups ($p = 0.689$).

### 3.2 Genetic Association Analysis

Allelic and genotypic distribution of the studied SNPs is presented in Table 3. For all the studied SNPs, genotype distribution in the cases and controls is presented in Table 3. The table includes information on the SNP, genotyping method, primer sequence, annealing temperature, restriction enzyme, and product size.

#### Table 1: Designed primers for genotyping of the studied SNPs.

| SNP          | Genotyping method | Primer sequence | Annealing temperature (°C) | RE         | Product size (bp) |
|--------------|-------------------|-----------------|----------------------------|------------|-------------------|
| rs1261084C/T | PCR-RFLP          | F: CAAAGTAGATTGATGTCATTCTCTAC<br>R: GCTCTGAACTGCAACATGTTTTTCG<br>F: GCACCCGCTCTGAGGAGATGG<br>R: CCGGGTCTTTGGCATTTGAC<br>F (T-allele): TCTTTATGCTAAAGGAATGAGA<br>R (common): TACCTCCATCCAGGGAGTCA | 55          | FokI<br>C: 405<br>A: 204 + 201 |
| rs10774053A/G| PCR-RFLP          | F: GCACCCGCTCTGAGGAGATGG<br>R: CCGGGTCTTTGGCATTTGAC<br>F (T-allele): TCTTTATGCTAAAGGAATGAGA<br>R (common): TACCTCCATCCAGGGAGTCA | 56          | MspI<br>A: 402<br>C: 201 + 201 |
| rs10466907G/T| ARMS-PCR          | F (G-allele): TCTTTATGCTAAAGGAATGAGA<br>R (common): TACCTCCATCCAGGGAGTCA | 55          | T or G: 250 |
| rs1625579A/C | Tetra-ARMS-PCR    | FO: GTATGAGAACATCAGGGTCAC<br>RO: CCAAAGGTCTCTAGTGCTTTGTAC<br>F (A-allele): GGAAGCTTATLAAACGTAGTT<br>GTT<br>F (C-allele): GGAAGCTTATLAAACGTAGTT<br>GTT | 62          | A or C: 192 |

F: forward; R: reverse; FO: forward outer; RO: reverse outer; SNP: single-nucleotide polymorphism; RFLP-PCR: restriction fragment length polymorphism polymerase chain reaction; ARMS-PCR: amplification refractory mutation system polymerase chain reaction; RE: restriction enzyme; BP: base pair.

![Figure 1](image1.png)

Figure 1: Gel electrophoretic separation of PCR products for (a) miR137 rs1625579, (b) CACNA1C rs10774053, (c) CACNA1C rs10466907, and (d) TCF4 rs1261084 polymorphisms.
### Table 2: Clinical and demographic characteristics of BD patients and controls.

| Parameter evaluated                  | BD (n, %) (mean ± SD) | BDI (n, %) (mean ± SD) | BDII (n, %) (mean ± SD) | Controls (n, %) (mean ± SD) | P value |
|--------------------------------------|-----------------------|------------------------|-------------------------|-----------------------------|---------|
| Age (year)                           |                       |                        |                         |                             |         |
| 18-29                                | 157 (62.3)            | 108 (59.0)             | 49 (71.0)                | 115 (54.0)                  | P1: 0.063 |
| 30-44                                | 85 (33.7)             | 65 (35.5)              | 20 (29.0)                | 79 (37.1)                   | P2: 0.062 |
| 45-64                                | 10 (4.0)              | 10 (5.5)               | 0                       | 17 (8.0)                    |         |
| >64                                  | 0                     | 0                      | 0                       | 2 (0.9)                     |         |
| Gender (female/male)                 | 72/180                | 53/130                 | 19/50                   | 62/151                      |         |
| BMI (kg/m2)                          | 23.25 ± 3.92          | 23.28 ± 4.23           | 23.19 ± 2.96            | 23.42 ± 2.80                |         |
| Age at onset (year)                  | 25.96 ± 9.71          | 25.84 ± 9.02           | 26.29 ± 11.40           | —                           | P2: 0.050 |
| Employment status                    |                       |                        |                         |                             |         |
| Full-time worker                     | 26 (10.3)             | 23 (12.6)              | 3 (4.3)                 | 111 (81.0)                  | P1: <0.001 |
| Part-time worker                     | 36 (14.3)             | 28 (15.3)              | 8 (11.6)                | 51 (58.6)                   | P2: 0.109 |
| Retired                              | 8 (3.2)               | 4 (2.2)                | 4 (5.8)                 | 0 (0)                       |         |
| Unemployed                           | 149 (59.1)            | 104 (56.8)             | 45 (65.2)               | 32 (17.7)                   |         |
| Other                                | 33 (13.1)             | 24 (13.1)              | 9 (13.0)                | 19 (38.8)                   |         |
| Family history of mood disorder      |                       |                        |                         |                             | P2: 0.689 |
| Presence                             | 162 (64.3)            | 119 (65.0)             | 43 (62.3)               |                             |         |
| Absence                              | 90 (35.7)             | 64 (35.0)              | 26 (37.7)               |                             |         |
| History of suicide attempt           |                       |                        |                         |                             | P2: 0.726 |
| Presence                             | 116 (46.0)            | 83 (45.4)              | 33 (47.8)               |                             |         |
| Absence                              | 136 (54.0)            | 100 (54.6)             | 36 (52.2)               |                             |         |
| History of anxiety disorders         |                       |                        |                         |                             | P2: 0.767 |
| Presence                             | 194 (77.0)            | 140 (76.5)             | 54 (78.3)               |                             |         |
| Absence                              | 58 (23.0)             | 43 (23.5)              | 15 (21.7)               |                             |         |
| Hospitalization in past 12 months    |                       |                        |                         |                             | P2: 0.712 |
| Once                                 | 158 (62.7)            | 116 (63.4)             | 42 (60.9)               |                             |         |
| Two or more                          | 94 (37.3)             | 67 (36.6)              | 27 (39.1)               |                             |         |
| Mood                                 |                       |                        |                         |                             | P2: 0.880 |
| Depressed                            | 86 (34.1)             | 62 (33.9)              | 24 (34.8)               |                             |         |
| Mania                                | 119 (47.2)            | 88 (48.1)              | 31 (44.9)               |                             |         |
| Mix                                  | 47 (18.7)             | 33 (18.0)              | 14 (20.3)               |                             |         |
| Episodes of mania/hypomania (per year)|                       |                        |                         |                             | P2: 0.519 |
| <4                                   | 191 (75.8)            | 142 (77.6)             | 49 (71.0)               |                             |         |
| 4-20                                 | 57 (22.6)             | 38 (20.8)              | 19 (27.5)               |                             |         |
| >20                                  | 4 (1.6)               | 3 (1.6)                | 1 (1.4)                 |                             |         |

BD: bipolar disorder; BMI: body mass index. P < 0.05 was considered statistically significant. P1: BD vs. control; P2: BDI vs. BDII.
controls was compatible with the Hardy-Weinberg equilibrium (HWE) (P value >0.05). The T allele of rs1261084C/T polymorphism significantly enhanced the risk of BD (OR = 1.36, 95% CI = 1.05 – 1.76, P = 0.021). The TT genotype in codominant 2 (TT vs. CC) models increased the risk of BD in our population (OR = 1.84, 95% CI = 1.12 – 3.02, P = 0.016, respectively). Similarly, the T allele in the dominant CC + CT vs. TT model enhanced BD risk by 1.61-fold (OR = 1.61, 95% CI = 1.06 – 2.45, P = 0.025). Regarding the rs10774053A/G polymorphism, the G allele (OR = 1.54, 95% CI = 1.19 – 1.99), as well as the GG genotype (OR = 1.57, 95% CI = 1.04 – 2.38, P = 0.032), enhanced the risk of BD in our population. Moreover, under the recessive (GG vs. AG + AA) and dominant (AA + AG vs. GG) modes of inheritance, increased BD risk was observed by 1.90 and 1.57–folds, respectively. For rs10466907G/T, the T allele was more frequent in BD subjects than in healthy subjects (OR = 1.33, 95% CI = 1.02 – 1.73, P = 0.034). In this case, the codominant 2 (TT vs. GG) model was correlated with enhanced risk of BD (OR = 1.94, 95% CI = 1.09 – 3.47, P = 0.025). Similarly, rs1625579A/C served as a risk factor for the onset of BD. The A allele of this SNP statistically increased the risk of BD by 1.47-fold (OR = 1.47, 95% CI = 1.14 – 1.91, P = 0.003). The CC genotype compared to AA genotype (codominant 2 model) caused a 2.12-fold increase in BD risk (OR = 2.12, 95% CI = 1.26 – 3.57, P = 0.004). Meanwhile, significant enhancement in BD risk was observed under the dominant AA + AC vs. CC (OR = 1.69, 95% CI = 1.08 – 2.63, P = 0.021) and recessive CC vs. AC + AA (OR = 1.64, 95% CI = 1.09 – 2.44, P = 0.016) contrasted genetic patterns.

Table 4 demonstrates the relationship between the genotype frequencies of studied variants and disease subtypes. Within-group comparison indicated a significant association between the frequency of GG genotype and GT genotypes of CACNA1C rs10466907G/T polymorphism among BD1 and BDII cases (P value =0.014).

The interaction analysis of studied variants is shown in Table 5. In this regard, some interactions with frequencies under 1% (in either BD cases or healthy individuals) were excluded. Among all combined genotypes in the control group, the CT/AG/GT/AC genotype of rs1261084/rs10774053/rs10466907/rs1625579 polymorphisms was more frequent, hence considered the reference genotype. Both TT/AG/GT/AA and TT/GG/GT/AC combinations of genotypes strongly enhanced the risk of BD (OR = 5.24, 95% CI = 1.06 – 25.97, P = 0.036 and OR = 5.76, 95% CI = 1.17 – 25.25, P <0.001, respectively).

3.3. Computational Findings. The genomic and transcriptomic sequences were obtained from the National Center for Biotechnology Information (NCBI), Ensembl, and UCSC Genome Browser databases for computational analyses. By employing the mirSNP database, we found that TCF4 rs1261084C/T is likely to produce and disrupt some miRNA binding sites. Specifically, the T allele of this variation creates a de novo binding site for hsa-miR-105-3p, while the C allele can break the hsa-miR-356 binding site. In addition, both alleles of rs1261084C/T can enhance the affinity of TCF4 to hsa-miR-3151 and hsa-miR-3180 (Table 6). Regarding rs10466907G/T polymorphism, the T allele can create a new binding site for hsa-miR-561-3p, while the G allele does not affect the miRNA binding sites (Table 6). In addition, to explore the role of the miRNAs above, the mirWadDB was recruited. We found that hsa-miR-105 targets insulin receptor substrate protein1 (IRS1), the serine/threonine kinase Akt, and 3-Phosphoinositide-dependent protein kinase-1 (PKD1) genes are all contributing to the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway (data not shown).

To determine the possible effects of rs10774053A/G polymorphism on splicing sites, the SpliceAid2 database was recruited. A 100 bp flanking region containing this SNP was introduced as a reference sequence. The results of this database revealed that rs10774053A/G developed a new splicing site in the presence of the G allele. In addition to the ETR-3 splicing factor shared between both A and G alleles, a SRp30c arginine/serine p splicing factor is created in the presence of the G allele (Figure 2).

ETR-3 contributes to the developmental regulation and stability of multiple miRNAs in the cytoplasm and nucleolus [43]. Furthermore, the SNAP2 database predicted the functional effects of sequence variants. We observed that methionine to valine substitution in position 1821 of CACNA1C protein potentially might alter the function of this protein (Figure 3).

A meaningful discrepancy in the free energy of A and/or C alleles of rs1625579 was noticed by the RNAfold database. A 20bp flanking region was introduced as a template sequence up and downstream of the SNP position. In the presence of the A allele, miR-137 has been found to be more stable than the C allele. The amount of the free energy of the thermodynamic ensemble is -1.76 kcal/mol and -1.34 kcal/mol, regarding A and C alleles, respectively (Figure 4).

4. Discussion

In the current study, we found that most BD cases were of the BDI subtype. Moreover, a large proportion of BD patients were experiencing mania at the time of recruitment. Furthermore, 59.1% of the enrolled patients were unemployed, which might not be surprising. Bauer et al. reported that frequent symptoms of BD, especially depression, preclude full-time responsibilities outside the home and contribute to disability in these patients [59]. In another study, Owen and coworkers showed that the relationship between social interaction and bipolar-related experiences is complex; however, BD is responsible for damaging social relationships and is associated with loss of social control via extreme mood states [60]. Genotyping results revealed that rs1261084C/T, rs10774053A/G, rs1625579A/C, and rs10466907G/T variants conferred an increased BD risk in a sample of the Iranian population. The most powerful increase in the risk of BD was observed under the codominant model of rs10774053G/G (OR = 2.23). Overall, enhanced risk of BD was noticed under the codominant homozygous, dominant, and allelic models of TCF4 rs1261084C/T, codominant homozygous and allelic models
of CACNA1C rs10466907G/T polymorphisms as well as codominant homozygous, dominant, recessive, and allelic models of the CACNA1C rs10774053A/G. Notably, the A allele of miR-137 rs1625579A/C significantly enhanced the risk of BD under the codominant homozygous, dominant, recessive, and allelic contrasted models. In addition, both TT/AG/GT/AA and TT/GG/GT/AC genotype combinations strongly increased the risk of BD in the participants.

Bioinformatics analyses indicated that the hsa-miR-105-3p binding site is created in the presence of the T allele, while the C allele disrupts a binding site related to hsa-miR-356. Moreover, the T allele of CACNA1C can create a new binding site for hsa-miR-561-3p. The rs10774053A/G polymorphism is likely to change the pattern of splicing sites in its position, while the G allele of this variant introduces a new splicing site for the SRp30c splicing factor. The M1821V substitution caused a functional change in the CACNA1C protein and must be validated using in vitro methods. We observed that the secondary structure of miR-137 is more stable in the presence of the A allele.  

Table 3: Allelic and genotypic distribution of miR-137 (rs1625579A/C), TCF4 (rs1261084C/T) and CACNA1C (rs10774053A/G, rs10466907G/T) polymorphisms.

| SNP            | BD, n (%) | Control, n (%) | Genetic model | OR (95% CI) | P value |
|----------------|-----------|----------------|---------------|-------------|---------|
| rs1261084C/T   |           |                |               |             |         |
| CC             | 54 (21.4) | 65 (30.5)      | 1 [reference] |             |         |
| CT             | 114 (45.3)| 93 (43.7)      | Codominant 1  | 1.48 (0.94-2.32) | 0.092   |
| TT             | 84 (33.3) | 55 (25.8)      | Codominant 2  | 1.84 (1.12-3.02) | 0.016   |
| HWE (P value)  | 0.192     | 0.068          | Dominant      | 1.61 (1.06-2.45) | 0.025   |
|                |           |                | Recessive     | 1.44 (0.96-2.15) | 0.078   |
|                |           |                | Overdominant  | 1.07 (0.74-1.54) | 0.733   |
| C              | 222 (44.0)| 217 (51.7)     | Allelic       | 1 [reference]  |         |
| T              | 282 (56.0)| 203 (48.3)     | Allelic       | 1.36 (1.05-1.76) | 0.021   |
| rs10774053A/G  |           |                |               |             |         |
| AA             | 56 (22.3) | 66 (31.0)      | 1 [reference] |             |         |
| AG             | 111 (44.0)| 102 (47.9)     | Codominant 1  | 1.28 (0.82-2.00) | 0.274   |
| GG             | 85 (33.7) | 45 (21.1)      | Codominant 2  | 2.23 (1.34-3.70) | 0.002   |
| HWE (P value)  | 0.089     | 0.632          | Dominant      | 1.57 (1.04-2.38) | 0.032   |
|                |           |                | Recessive     | 1.90 (1.25-2.89) | 0.003   |
|                |           |                | Overdominant  | 0.86 (0.59-1.24) | 0.408   |
| A              | 223 (44.2)| 234 (54.9)     | Allelic       | 1 [reference]  |         |
| G              | 281 (55.8)| 192 (45.1)     | Allelic       | 1.54 (1.19-1.99) | 0.001   |
| rs10466907G/T  |           |                |               |             |         |
| GG             | 69 (27.4) | 74 (34.7)      | 1 [reference] |             |         |
| GT             | 136 (54.0)| 113 (53.1)     | Codominant 1  | 1.29 (0.85-1.95) | 0.224   |
| TT             | 47 (18.6) | 26 (12.2)      | Codominant 2  | 1.94 (1.09-3.47) | 0.025   |
| HWE (P value)  | 0.164     | 0.085          | Dominant      | 1.41 (0.95-2.10) | 0.087   |
|                |           |                | Recessive     | 1.65 (0.98-2.77) | 0.057   |
|                |           |                | Overdominant  | 1.04 (0.72-1.50) | 0.843   |
| G              | 274 (54.4)| 261 (61.3)     | Allelic       | 1 [reference]  |         |
| T              | 230 (45.6)| 165 (38.7)     | Allelic       | 1.33 (1.02-1.73) | 0.034   |
| rs1625579A/C   |           |                |               |             |         |
| CC             | 44 (17.5) | 56 (26.3)      | 1 [reference] |             |         |
| AC             | 118 (46.8)| 103 (48.4)     | Codominant 1  | 1.46 (0.91-2.34) | 0.119   |
| AA             | 90 (35.7) | 54 (25.3)      | Codominant 2  | 2.12 (1.26-3.57) | 0.004   |
| HWE (P value)  | 0.620     | 0.631          | Dominant      | 1.69 (1.08-2.63) | 0.021   |
|                |           |                | Recessive     | 1.64 (1.09-2.44) | 0.016   |
|                |           |                | Overdominant  | 0.94 (0.65-1.35) | 0.742   |
| C              | 206 (40.9)| 215 (50.5)     | Allelic       | 1 [reference]  |         |
| A              | 298 (59.1)| 211 (49.5)     | Allelic       | 1.47 (1.14-1.91) | 0.003   |

BD: bipolar disorder; SNP: single-nucleotide polymorphism; CI: confidence interval; OR: odd ratio; HWE: Hardy-Weinberg equilibrium. Codominant 1 and Codominant 2 represent the heterozygous and homozygous codominant models, respectively. P < 0.05 is considered statistically significant.
To the best of our knowledge, this is the first study to explore the association between SNPs in miR-137 and its downstream genes and BD risk. It is hypothesized that SNPs located in the 3′-untranslated region (3′-UTR) of genes, such as TCF4 rs1261084C/T and CACNA1C rs10774053A/G, can influence the miRNA binding sites and gene expression. Moreover, the CACNA1C rs10466907G/T is a missense variation and displays a change in amino acid (methionine to valine). Finally, rs1625579A/C is located in the pri-miR-137 region, where nucleotide exchange may affect the maturation process of miRNA. This might result in changes in miRNA expression and its regulatory pathways.

As a candidate gene, CACNA1C is located on chromosome 12p13.33 and encodes the Cav1.2 channel [61]. These types of channels enable the influx of extracellular Ca2+

| Disease type | Case genotypes of TCF4 rs1261084C/T | Test of Within-group comparison | Case genotypes of CACNA1C rs10774053A/G | Test of Within-group comparison |
|--------------|-----------------------------------|---------------------------------|---------------------------------------|---------------------------------|
| CC N=54 CT N=114 TT N=84 | 41 (22.4) 82 (44.8) 60 (32.8) X²: 0.384 P: 0.825 | 36 (19.7) 85 (46.4) 62 (33.9) P: 0.585 | 20 (29.0) 26 (37.7) 23 (33.3) P: 0.938 |
| BDI | | | |
| BDI | 13 (18.8) 32 (46.4) 24 (34.8) P: 0.036 | | |

| Disease type | Case genotypes of CACNA1C rs10466907G/T | Test of Within-group comparison | Case genotypes of miR-137 rs1625579A/C | Test of Within-group comparison |
|--------------|---------------------------------------|---------------------------------|---------------------------------------|---------------------------------|
| CC N=69 GT N=136 TT N=47 | 57 (31.1) 90 (49.2) 36 (19.7) X²: 6.68 P: 0.036 | 65 (35.5) 82 (44.8) 36 (19.7) X²: 2.46 P: 0.292 | |
| BDI | | | |
| BDI | 12 (17.4) 46 (66.7) 11 (15.9) P: 0.036 | 25 (36.2) 36 (52.2) 8 (11.6) P: 0.117 | |

BD: bipolar disorder; BDI: bipolar disorder type I; BDII: bipolar disorder type II; P1: wild-type homozygote vs. heterozygote genotype; P2: wild-type homozygote vs. mutant homozygote; P3: heterozygote vs. mutant homozygote. X² and P represent the amount of Chi-square and asymptotic significance (2-sided), respectively. P<0.05 was considered statistically significant.

| rs1261084C/T | rs10774053A/G | rs10466907G/T | rs1625579A/C | BD (%) | Control (%) | OR (95% CI) | P value* |
|--------------|--------------|--------------|-------------|--------|-------------|------------|---------|
| CT | AG | GT | AC | 7 (2.8) | 11 (5.2) | 1 [reference] | 0.03 |
| CC | AA | GT | AA | 7 (2.8) | 2 (0.9) | 5.50 (0.88-34.46) | 0.03 |
| CC | AA | GT | AC | 2 (0.8) | 7 (3.3) | 0.45 (0.07-2.81) | 0.36 |
| CC | AG | GT | AC | 5 (2.0) | 8 (3.8) | 0.98 (0.23-4.25) | 0.72 |
| CC | AG | GT | CC | 3 (1.2) | 8 (3.8) | 0.59 (0.11-3.01) | 0.52 |
| CC | GG | GT | AC | 8 (3.2) | 3 (1.4) | 4.19 (0.82-21.40) | 0.08 |
| CT | AA | GG | AC | 4 (1.6) | 5 (2.3) | 1.26 (0.25-6.36) | 0.76 |
| CT | AA | GT | AC | 6 (2.4) | 4 (1.9) | 2.36 (0.49-11.45) | 0.28 |
| CT | AG | GG | AC | 7 (2.8) | 5 (2.3) | 2.20 (0.50-9.75) | 0.28 |
| CT | AG | GT | AA | 11 (4.4) | 8 (3.8) | 2.16 (0.58-8.04) | 0.24 |
| CT | AG | GT | CC | 9 (3.6) | 6 (2.8) | 2.36 (0.58-9.580 | 0.20 |
| CT | GG | GT | AC | 4 (1.6) | 7 (3.3) | 0.90 (0.19-4.24) | 0.88 |
| CT | GG | GT | AA | 7 (2.8) | 2 (0.9) | 5.50 (0.88-34.46) | 0.04 |
| CT | GG | GT | AC | 9 (3.6) | 6 (2.8) | 2.36 (0.58-9.58) | 0.20 |
| TT | AG | GG | AC | 5 (2.0) | 6 (2.8) | 1.31 (0.29-5.98) | 0.72 |
| TT | AG | GT | AA | 10 (4.0) | 3 (1.4) | 5.24 (1.06-25.97) | 0.036 |
| TT | AG | GT | AC | 14 (5.6) | 9 (4.2) | 2.44 (0.69-8.66) | 0.16 |
| TT | AG | GT | CC | 2 (0.8) | 7 (3.3) | 0.45 (0.07-2.81) | 0.36 |
| TT | GG | GT | AC | 11 (4.5) | 3 (1.4) | 5.76 (1.17-25.25) | <0.001 |

OR: odd ratio; CI: confidence interval; BD: bipolar disorder. *P values were corrected for multiple testing. *P<0.05 was considered statistically significant.
upon depolarization. Cav1.2 channels are expressed in neuronal cells and play various pivotal functions, including regulating Ca2+ secretion [62]. The TCF4 encoding gene resides on chromosome 18q21.2 [63]. TCF4 is a transcription factor from the helix-loop-helix (HLH) family, regulating many different genes contributing to cell differentiation and neurodevelopment [64]. Some evidence revealed that mutations in the TCF4 gene were associated with Pitt-Hopkins syndrome, a rare mental disease known as mental retardation. In addition, deletions in this gene have been recognized as a risk factor for autistic-like behaviors [65, 66].

The miR-137 and its four putative target genes, including CACNA1C, TCF4, CSMD1, and C10orf26, have gained much attention as they are involved in a series of psychiatric conditions [67]. Additionally, luciferase-based reporter assay analysis confirmed these genes as experimentally validated

| Gene        | miRNA         | SNP       | Effect   | Allele | Energy | Conservation |
|-------------|---------------|-----------|----------|--------|--------|--------------|
| TCF4        | Hsa-miR-105-3p| rs1261084 | Create   | C      | -18.66 | 0.002        |
| TCF4        | Hsa-miR-356   | rs1261084 | Break    | T      | -22.47 | 0.002        |
| TCF4        | Hsa-miR-3151  | rs1261084 | Enhance  | C      | -23.24 | 0.036        |
| TCF4        | Hsa-miR-3180  | rs1261084 | Enhance  | T      | -22.26 | 0.036        |
| CACNA1C     | Hsa-miR-561-3p| rs10466907| Create   | T      | -19.77 | 0.028        |

SNP: single-nucleotide polymorphism; miRNA: microRNA.
targets of the miR-137 [37]. Differential expression studies showed that miR-137 was upregulated in patients suffering from SCZ compared to healthy controls [68]. New evidence suggests that the expression level of miR-137 and its down-stream targets is strongly correlated with the development, differentiation, and maturation of the nervous system [69] and contributes to the etiology of BD [32]. In 2014, Duan et al. reported that a rare functional noncoding SNP at the GWAS-implicated miR-137/miR2682 locus might be associated with risk of SCZ as well as BD [70]. Using neuronal-like SH-SY5Y cells, Strazisar et al. discovered that miR-137 SNPs might impact synaptogenesis and neural transmission gene sets [71]. As an intronic variant of miR-137, rs1625579A/C is located on chromosome 1p21.3. It was previously shown that rs1625579A/C influences the risk of SCZ in a sample of the Chinese Han population [72]. An abnormal level of mature miR-137 was recently found in the cerebral cortex of patients carrying the T allele of miR-137 rs1625579A/C. However, the underlying mechanism by which this SNP dys-regulates miR-137 processing is not clear yet [30].

In 2012, Whalley et al. showed that miR-137 rs1625579A/C SNP affects brain function in people at high genetic risk of BD [32]. In 2016, Zhang et al. performed a meta-analysis and found that this SNP enhances the risk of SCZ under allelic, recessive, and additive models [72]. Guan et al. showed that SNPs in miR-137 (rs1625579A/C) and its target gene, CACNA1C (rs10774053A/G and rs10466907G/T) polymorphisms, are associated with enhanced risk of SCZ risk in the Han Chinese population [17]. In agreement with these reports, we observed a positive association between CACNA1C SNPs and BD in our population. Moreover, we found a positive association between miR-137 rs1625579A/C SNP and BD risk. Another study by Lin et al. showed that CACNA1C rs10466907G/T affects cognitive recovery in patients with BD following a 6-week open-label trial [73].

As a novel schizophrenia risk variant at miR-137, the rs1625579A/C has been previously associated with SCZ; however, the results were inconclusive. In this connection, van Erp et al. reported that genotypes of the miR-137 rs1625579A/C variation are associated with dorsolateral pre-frontal cortex hyperactivation, a condition that is considered a measure of brain inefficiency in SCZ cases [74]. By performing a meta-analysis on 2847 patients and 3018 controls of Chinese ancestry, Zhang et al. reported a significant association between this SNP and risk of SCZ under allelic T vs. G and recessive TT vs. GT + GG genetic patterns. In contrast, no significant link was observed between the SNP and SCZ under the dominant TT + GT vs. GG genetic model [72]. In 2013, Cummings et al. genotyped 821 cases with SCZ, schizoaffective disorder, and BDI. They proposed that risk allele carriers of the miR-137 rs1625579A/C had more cognitive deficits in terms of episodic memory and attentional control. In other words, mood-congruent psychotic symptoms and specific cognitive deficits were found to be significantly linked to this SNP [75]. In another study, Pu and Xiao pooled the genotypic results of 30843 Asian individuals and evidenced no statistical correlation between miR-137 rs1625579A/C and risk of SCZ [76].

In a study in 2016, Deniz Ozel et al. assessed genotype frequencies of the TCF4 gene rs9960767 polymorphism in 95 patients with BD and 108 healthy controls of a Turkish population. Their findings revealed that this variation does not appear to be an independent risk factor for BD; nonetheless, their findings could be biased due to the small size of the studied population [77]. Few reports have established the link between SCZ and TCF4 rs1261084C/T. Using multiplex polymerase chain reaction- (PCR-) SNPscan assay, Gao et al. genotyped 448 SCZ cases and 628 controls from a northwest Han Chinese population and found no significant link between TCF4 rs1261084C/T and the disease. However, by combining

![Figure 4: The secondary structure of hsa-miR-137 regarding miR-137 rs1625579A/C. The results revealed that the local secondary structure of hsa-miR-137 is more stable in the presence of the A allele. The amount of the free energy of the thermodynamic ensemble is -1.76 kcal/mol and -1.34 kcal/mol, regarding A and C alleles, respectively. In the RNAfold server, each base is colored by the positional entropy and probability of forming pairs with paired bases and remaining unpaired bases. The red color represents the highest entropy and probability of forming pairs with paired bases, whereas, purple represents the lowest entropy.](image-url)
the results of their study with previously published reports, they found a noteworthy association between TCF4 rs1261084C/T and SCZ susceptibility [78]. Results of an investigation by Hui et al. indicated that another SNP in the TCF4 gene, rs2958182A/T, affected SCZ risk and was associated with lower cognitive performance in the language in these patients [79]. These observations suggest that this noncoding variation might contribute to the development of psychiatric diseases. Regarding the CACNA1C polymorphisms, only one report has highlighted the association of CACNA1C rs10466907 with BD. In their study, Lin et al. performed an open-label trial on 192 BD cases suffering a major depressive episode. They found that after 6 weeks, the rs10466907GT genotype did not significantly enhance the executive function total scores on the Wisconsin Card Sorting Test compared with carriers of the TT genotype [73]. These observations shed light on the contribution of CACNA1C SNPs to cognitive recovery from depression in patients diagnosed with BD. Another SNP in the CACNA1C encoding gene, rs10848683C/T, confers a higher risk of developing psychiatric disorders, including BD and SCZ, in subjects with family backgrounds [80]. Altogether, in our population, we observed significant links between the tested SNPs and BD risk. Hence, the miR-137 and its target genes might be involved in the pathogenesis of BD.

Our study has limitations. First, our sample size was modest, especially for stratified analyses. Hence, our findings should be validated through replicated studies using a larger sample size. Second, the frequency of the minor alleles of rs10774053 was not entirely consistent throughout the different populations in the world. This might be due to the limited sample size. According to our findings, the frequency of the minor alleles of rs1261084C/T, rs10774053A/G, rs10466907G/T, and rs1625579A/C were found to be 0.48, 0.45, 0.38, and 0.49. In addition, the frequency of genetic variations may be varied through different populations. For example, based on the information provided by the ensemble database (available at https://asia.ensembl.org/index.html), the T allele of rs1261084 is more frequent than the C allele in the majority of populations, even though it acted as the minor allele in our population. Moreover, in the case of rs10466907, the T allele is less frequent in the African and our populations; however, it cannot be applied to other populations. Finally, although stratified analyses were conducted, additional subtle stratified analyses should be done in further studies, e.g., in subgroups of early-onset and late-onset BD cases.

5. Conclusion

Our results provided evidence for the involvement of genetic variations in miR-137 and its target genes, TCF4 and CACNA1C, in the onset and development of BD. We have found that all the studied SNPs are positively associated with BD susceptibility. Future studies with a larger sample size are required to confirm these preliminary results. Further functional studies on determining the potential epistatic interactions between miR-137 and its putative targets would be desirable to elucidate the etiology of BD and discover novel strategies to treat this severe mental disorder.

Data Availability

The raw data are available upon reasonable requests.

Ethical Approval

The local ethics committee of Zahedan University of Medical Sciences (Zahedan, Iran) approved the study design (Ethical code: IR.ZAUMS.REC.1398.359, webpages can be found at https://ethics.research.ac.ir/EthicsProposalViewEn.php?id=105037).

Consent

Explicit informed consent was taken from each participant.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this article.

Authors’ Contributions

SS and RS were responsible for the conceptualization; MAM, SS, MHN, SHM, JB, and KH were assigned for the original draft preparation, SS, RS, JB, KH, and MS were tasked for the review and editing; RS and MS were charged for the supervision. All authors have read and agreed to the published version of the manuscript. Mohammad Ali Mokhtari (MAM) and Saman Sargazi (SS) equally contributed to this study.

Acknowledgments

The authors would like to thank the staff of Baharan psychiatric hospital in Zahedan in southeast Iran for their helpful collaboration. This work was funded by Zahedan University of Medical Sciences, Zahedan, Iran (Grant No. 9666), and Medical School, University of Pécs, Pécs, Hungary (KA-2021-13, KA-2020-27).

References

[1] B. N. Frey, A. C. Andreazza, F. G. Nery et al., “The role of hippocampus in the pathophysiology of bipolar disorder,” Behavioural Pharmacology, vol. 18, no. 5-6, pp. 419–430, 2007.
[2] M. B. First, User’ guide for the structured clinical interview for DSM-IV axis I disorders SCID-I: clinician version, American Psychiatric Pub, 1997.
[3] S. Pini, V. de Queiroz, D. Pagnin et al., “Prevalence and burden of bipolar disorders in European countries,” European Neuropsychopharmacology, vol. 15, no. 4, pp. 425–434, 2005.
[4] A. J. Ferrari, E. Stockings, J. P. Khoo et al., “The prevalence and burden of bipolar disorder: findings from the global burden of disease study 2013,” Bipolar Disorders, vol. 18, no. 5, pp. 440–450, 2016.
[5] H. He, C. Hu, Z. Ren, L. Bai, F. Gao, and J. Lyu, “Trends in the incidence and DALYs of bipolar disorder at global, regional, and national levels: results from the global burden of disease study 2017,” Journal of Psychiatric Research, vol. 125, pp. 96–105, 2020.
[6] M.-R. Mohammadi, H. Davidian, A. Noorbala et al., “An epidemiological survey of psychiatric disorders in Iran,” Clinical Practice and Epidemiology in Mental Health, vol. 1, no. 1, pp. 16–18, 2005.

[7] A. J. Ferrari, A. J. Baxter, and H. A. Whiteford, “A systematic review of the global distribution and availability of prevalence data for bipolar disorder,” Journal of Affective Disorders, vol. 134, no. 1–3, pp. 1–13, 2011.

[8] J. N. Gaab, A. F. Nassief, and A. Al-Assi, “Simple salting-out method for genomic DNA extraction from whole blood,” Tikrit Journal of Pure Science, vol. 16, no. 2, p. 1813, 2011.

[9] P. Lichtenstein, B. H. Yip, C. Björk et al., “Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study,” The Lancet, vol. 373, no. 9659, pp. 234–239, 2009.

[10] M. M. Nöthen, V. Nieratschker, S. Cichon, and M. Rietschel, “A systematic review of the genetics of major psychoses,” Dialogues in Clinical Neuroscience, vol. 12, no. 1, pp. 85–93, 2010.

[11] N. Craddock and P. Sklar, “Genetics of bipolar disorder,” The Lancet, vol. 381, no. 9878, pp. 1654–1662, 2013.

[12] B. Kerner, “Genetics of bipolar disorder,” The Application of Clinical Genetics, vol. 7, p. 33, 2014.

[13] T. W. Mühleisen, M. Leber, T. G. Schulze et al., “The IL12 Family of Cytokines,” Nutrients, vol. 6, no. 1, pp. 1–8, 2014.

[14] A. Yosifova, T. Mushiroda, M. Kubo et al., “Genome-wide association study of bipolar disorder in the Bulgarian population,” Genes, Brain and Behavior, vol. 10, no. 7, pp. 789–797, 2011.

[15] D. Chen, X. Jiang, N. Akula et al., “Genome-wide association study meta-analysis of European and Asian-ancestry samples identifies three novel loci associated with bipolar disorder,” Molecular Psychiatry, vol. 18, no. 2, pp. 195–205, 2013.

[16] P. F. Sullivan, M. J. Daly, and M. O’Donovan, “Genetic architectures of psychiatric disorders: the emerging picture and its implications,” Nature Reviews Genetics, vol. 13, no. 8, pp. 537–551, 2012.

[17] F. Guan, B. Zhang, T. Yan et al., “miR-137 gene and target gene CACNA1C of miR-137 contribute to schizophrenia susceptibility in Han Chinese,” Schizophrenia Research, vol. 152, no. 1, pp. 97–104, 2014.

[18] N. J. Beveridge, E. Gardiner, A. P. Carroll, P. A. Tooney, and M. J. Cairns, “Schizophrenia is associated with an increase in cortical miRNA biogenesis,” Molecular Psychiatry, vol. 15, no. 12, pp. 1176–1189, 2010.

[19] A. H. Kim, M. Reimers, B. Maher et al., “MicroRNA expression profiling in the prefrontal cortex of individuals affected with schizophrenia and bipolar disorder,” Schizophrenia Research, vol. 124, no. 1–3, pp. 183–191, 2010.

[20] N. Craddock, M. C. O’Donovan, and M. J. Owen, “The genetics of schizophrenia and bipolar disorder: dissecting psychosis,” Journal of Medical Genetics, vol. 42, no. 3, pp. 193–204, 2005.

[21] Consortium, I.S., “Common polygenic variation contributes to risk of schizophrenia that overlaps with bipolar disorder,” Nature, vol. 460, no. 7256, p. 748, 2009.

[22] G.-M. Lin, Y. J. Chen, D. J. Kuo et al., “Cancer incidence in patients with schizophrenia or bipolar disorder: a nationwide population-based study in Taiwan, 1997–2009,” Schizophrenia Bulletin, vol. 39, no. 2, pp. 407–416, 2013.

[23] C. Catalanotto, C. Cogoni, and G. Zardo, “MicroRNA in control of gene expression: an overview of nuclear functions,” International Journal of Molecular Sciences, vol. 17, no. 10, p. 1712, 2016.

[24] A. M. Krichevsky, K. S. King, C. P. Donahue, K. Khrapko, and K. S. Kosik, “A microRNA array reveals extensive regulation of microRNAs during brain development,” RNA, vol. 9, no. 10, pp. 1274–1281, 2003.

[25] R. Pedra, J. Malvekrid, L. Hambry, M. Åkerblom, and J. Jakobsson, “miRNAs in brain development,” Experimental Cell Research, vol. 321, no. 1, pp. 84–89, 2014.

[26] M. G. Banigan, P. F. Kao, J. A. Kozubek et al., “Differential expression of exosomal microRNAs in prefrontal cortices of schizophrenia and bipolar disorder patients,” PLoS One, vol. 8, no. 1, article e48814, 2013.

[27] B. H. Miller, Z. Zeier, L. Xi et al., “MicroRNA-132 deregulation in schizophrenia has implications for both neurodevelopment and adult brain function,” Proceedings of the National Academy of Sciences, vol. 109, no. 8, pp. 3125–3130, 2012.

[28] D. M. Santarelli, N. J. Beveridge, P. A. Tooney, and M. J. Cairns, “Upregulation of microRNA expression in the dorsolateral prefrontal cortex Brodmann area 46 in schizophrenia,” Biological Psychiatry, vol. 69, no. 2, pp. 180–187, 2011.

[29] J. Yin, J. Lin, L. Luo et al., “miR-137: a new player in schizophrenia,” International Journal of Molecular Sciences, vol. 15, no. 2, pp. 3262–3271, 2014.

[30] L. Guella, A. Sequeira, B. Rollins et al., “Analysis of miR-137 expression and rs165579 in dorsolateral prefrontal cortex,” Journal of Psychiatric Research, vol. 47, no. 9, pp. 1215–1221, 2013.

[31] R. D. Smrt, K. V. Sulwach, L. R. Pfeiffer et al., “MicroRNA miR-137 regulates neuronal maturation by targeting ubiquitin ligase mind bomb-1,” Stem Cells, vol. 28, no. 6, pp. 1060–1070, 2010.

[32] H. C. Whalley, M. Pampeyer, L. Romaniuk et al., “Impact of a microRNA _miR137_ susceptibility variant on brain function in people at high genetic risk of schizophrenia or bipolar disorder,” Neuropsychopharmacology, vol. 37, no. 12, pp. 2720–2729, 2012.

[33] A. H. Kim, E. K. Parker, V. Williamson, G. O. McMichael, A. H. Fanous, and V. I. Vladimirov, “Experimental validation of candidate schizophrenia gene CACNA1C and C10orf26 as targets for hsa-miR-137,” Schizophrenia Research, vol. 141, no. 1, pp. 60–64, 2012.

[34] C. Wright, V. D. Calhoun, S. Ehrlich, L. Wang, J. A. Turner, and N. I. Bizzozero, “Meta gene set enrichment analyses link miR-137-regulated pathways with schizophrenia risk,” Frontiers in Genetics, vol. 6, p. 147, 2015.

[35] G. Hindle, S. Bahrami, N. E. Steen et al., “Characterising the shared genetic determinants of bipolar disorder, schizophrenia and risk-taking,” Translational Psychiatry, vol. 11, no. 1, pp. 1–10, 2021.

[36] M. A. Ferreira, M. C. O’Donovan, Y. A. Meng et al., “Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder,” Nature Genetics, vol. 40, no. 9, pp. 1056–1058, 2008.

[37] E. Kwon, W. Wang, and L. Tsai, “Validation of schizophrenia-associated genes CSM1D, C10orf26, CACNA1C and TCF4 as miR-137 targets,” Molecular Psychiatry, vol. 18, no. 1, pp. 11–12, 2013.

[38] N. Craddock, M. C. O’Donovan, and M. J. Owen, “Genes for schizophrenia and bipolar disorder? Implications for...
psychiatric nosology,” Schizophrenia Bulletin, vol. 32, no. 1, pp. 9–16, 2006.

[39] A. L. Moon, N. Haan, L. S. Wilkinson, K. L. Thomas, and J. Hall, “CACNA1C: association with psychiatric disorders, behavior, and neurogenesis,” Schizophrenia Bulletin, vol. 44, no. 5, pp. 958–965, 2018.

[40] N. Dedic, M. L. Pöhlmann, J. S. Richter et al., “Cross-disorder risk gene CACNA1C differentially modulates susceptibility to psychiatric disorders during development and adulthood,” Molecular Psychiatry, vol. 23, no. 3, pp. 533–543, 2018.

[41] A. Flora, J. J. Garcia, C. Thaller, and H. Y. Zoghbi, “The E-protein Tcf4 interacts with Math1 to regulate differentiation of a specific subset of neuronal progenitors,” Proceedings of the National Academy of Sciences, vol. 104, no. 39, pp. 15382–15387, 2007.

[42] M. M. Brzózka, K. Radyushkin, S. P. Wichert, H. Ehrenreich, and M. J. Rossner, “Cognitive and sensorimotor gating impairments in transgenic mice overexpressing the schizophrenia susceptibility gene Tcf4 in the brain,” Biological Psychiatry, vol. 68, no. 1, pp. 33–40, 2010.

[43] S. Sargazi, F. Mirani Sargazi, M. Heidari Nia et al., “Functional variants of miR-143 are associated with schizophrenia susceptibility: a preliminary population-based study and bioinformatics analysis,” Biochemical Genetics, vol. 60, no. 3, pp. 868–881, 2022.

[44] S. Sargazi, M. Heidari Nia, R. Saravani, M. Jafari Shahroudi, D. Jahantigh, and M. Shakiba, “IGF2BP2 polymorphisms as genetic biomarkers for either schizophrenia or type 2 diabetes mellitus: a case-control study,” Gene Reports, vol. 20, p. 100680, 2020.

[45] S. Sargazi, M. Heidari Nia, R. Sheervanilou et al., “Relationship between single nucleotide polymorphisms of GRHL3 and schizophrenia susceptibility: a preliminary case-control study and bioinformatics analysis,” International Journal of Molecular and Cellular Medicine, vol. 9, no. 2, pp. 154–164, 2020.

[46] M. H. Nia, M. J. Shahroudi, R. Saravani, S. Sargazi, M. Moudi, and A. Mojahed, “Relationship between P2X4R gene variants and the risk of schizophrenia in south-east of Iran: a preliminary case-control study and in silico analysis,” Iranian Journal of Public Health, vol. 50, no. 5, pp. 978–989, 2021.

[47] S. Sargazi, M. Mirani Sargazi, M. Moudi et al., “Impact of proliferator-activated receptor γ gene polymorphisms on risk of schizophrenia: a case-control study and computational analyses,” Iranian Journal of Psychiatry, vol. 15, no. 4, pp. 286–296, 2020.

[48] S. Sargazi, A. Zahedi Abghari, S. Mirinejad et al., “Long Non-coding RNA HOTAIR Polymorphisms and Susceptibility to Bipolar Disorder: A Preliminary Case–Control Study,” Nucleosides, Nucleotides & Nucleic Acids, vol. 41, no. 7, pp. 684–701, 2022.

[49] D. C. Steffens, D. G. Blazer, and J. L. Beyer, “Clinical entities listed as mood disorders in DSM-5 (American Psychiatric Association 2013) relevant to depression in elderly patients include (1) bipolar disorder, (2) major depressive disorder (with or without psychotic features), and (3) persistent depressive disorder (dysthymia). Of note, two key changes in DSM-5 pertinent to older adults are elimination of minor depression from,” Clinical Manual of Geriatric Psychiatry, p. 125, 2013.

[50] M. B. First, A. E. Skodol, D. S. Bender, and J. M. Oldham, User’s Guide for the Structured Clinical Interview for the DSM-5® Alternative Model for Personality Disorders (SCID-5-AMPD), American Psychiatric Pub, 2017.

[51] M. Poodineh, R. Saravani, M. Mirhosseini, and S. Sargazi, “Association of two methylenetetrahydrofolate reductase polymorphisms (rs1801133, rs1801131) with the risk of type 2 diabetes in south-east of Iran,” Reports of Biochemistry & Molecular Biology, vol. 8, no. 2, pp. 178–183, 2019.

[52] C. Pourzand and P. Cerutti, “Genotypic mutation analysis by RFLP/PCR,” Mutation Research, Fundamental and Molecular Mechanisms of Mutagenesis, vol. 288, no. 1, pp. 113–121, 1993.

[53] R. F. V. Medrano and C. A. De Oliveira, “Guidelines for the tetra-primer ARMS–PCR technique development,” Molecular Biotechnology, vol. 56, no. 7, pp. 599–608, 2014.

[54] M. Noordzij, G. Tripepi, F. W. Dekker, C. Zoccali, M. W. Tanck, and K. J. Jager, “Sample size calculations: basic principles and common pitfalls,” Nephrology, Dialysis, Transplantation, vol. 25, no. 5, pp. 1388–1393, 2010.

[55] C. Liu, F. Zhang, T. Li et al., “mirSNP, a database of polymorphisms altering miRNA target sites, identifies miRNA-related SNPs in GWAS SNPs and eQTLs,” BMC Genomics, vol. 13, no. 1, pp. 1–10, 2012.

[56] F. Piva, M. Giulietti, A. B. Burini, and G. Principato, “SpliceAid 2: a database of human splicing factors expression data and RNA target motifs,” Human Mutation, vol. 33, no. 1, pp. 81–85, 2012.

[57] Y. Bromberg and B. Rost, “SNAP: predict effect of non-synonymous polymorphisms on function,” Nucleic Acids Research, vol. 35, no. 11, pp. 3823–3835, 2007.

[58] S. S. Das, P. Saha, and N. Chakravorty, “miRwayDB: a database for experimentally validated microRNA-pathway associations in pathophysiological conditions,” Database, p. 2018, 2018.

[59] M. Bauer, T. Glenn, P. Grof et al., “Frequency of subsyndromal symptoms and employment status in patients with bipolar disorder,” Social Psychiatry and Psychiatric Epidemiology, vol. 44, no. 7, pp. 515–522, 2009.

[60] R. Owen, P. Gooding, R. Dempsey, and S. Jones, “The reciprocal relationship between bipolar disorder and social interaction: a qualitative investigation,” Clinical Psychology & Psychotherapy, vol. 24, no. 4, pp. 911–918, 2017.

[61] C. Mio, N. Passon, F. Baldan et al., “CACNA1C: haplinsufficiency accounts for the common features of interstitial 12p13.33 deletion carriers,” European Journal of Medical Genetics, vol. 63, no. 4, p. 103843, 2020.

[62] G. W. Zamponi, Voltage-gated calcium channels, Springer, 2005.

[63] J. A. Rosenfeld, K. Leppig, B. C. Ballif et al., “Genotype-phenotype analysis of TCF4 mutations causing Pitt-Hopkins syndrome shows increased seizure activity with missense mutations,” Genetics in Medicine, vol. 11, no. 11, pp. 797–805, 2009.

[64] H. Stefansson, R. A. Ophoff, S. Steinberg et al., “Common variants conferring risk of schizophrenia,” Nature, vol. 460, no. 7256, pp. 744–747, 2009.

[65] J. Amiel, M. Rio, L. Pontual et al., “Mutations in TCF4, encoding a class I basic Helix-Loop-Helix transcription factor, are responsible for Pitt-Hopkins syndrome, a severe epileptic encephalopathy associated with autonomic dysfunction,” The American Journal of Human Genetics, vol. 80, no. 5, pp. 988–993, 2007.

[66] L. O’Donnell, B. Soilleau, P. Heard et al., “Genetic determinants of autism in individuals with deletions of 18q,” Human Genetics, vol. 128, no. 2, pp. 155–164, 2010.

[67] Psychiatric GWAS Consortium Bipolar Disorder Working Group, “Large-scale genome-wide association analysis of
bipolar disorder identifies a new susceptibility locus near ODZ4,” Nature Genetics, vol. 43, no. 10, p. 977, 2011.

[68] B.-Y. Chen, J. J. Lin, M. K. Lu, H. P. Tan, F. L. Jang, and S. H. Lin, “Neurodevelopment regulators miR-137 and miR-34 family as biomarkers for early and adult onset schizophrenia,” NPJ Schizophrenia, vol. 7, no. 1, pp. 1–9, 2021.

[69] E. Mahmoudi and M. Cairns, “miR-137: an important player in neural development and neoplastic transformation,” Molecular Psychiatry, vol. 22, no. 1, pp. 44–55, 2017.

[70] J. Duan, J. Shi, A. Fiorentino et al., “A rare functional noncoding variant at the GWAS-implicated miR137/miR2682 locus might confer risk to schizophrenia and bipolar disorder,” The American Journal of Human Genetics, vol. 95, no. 6, pp. 744–753, 2014.

[71] M. Strazisar, S. Cammaerts, K. van der Ven et al., “miR137 variants identified in psychiatric patients affect synaptogenesis and neuronal transmission gene sets,” Molecular Psychiatry, vol. 20, no. 4, pp. 472–481, 2015.

[72] P. Zhang, Y. Bian, N. Liu et al., “The SNP rs1625579 in miR-137 gene and risk of schizophrenia in Chinese population: a meta-analysis,” Comprehensive Psychiatry, vol. 67, pp. 26–32, 2016.

[73] K. Lin, G. Xu, L. Shi et al., “CACNA1C polymorphisms impact cognitive recovery in patients with bipolar disorder in a six-week open-label trial,” Scientific Reports, vol. 7, no. 1, pp. 1–8, 2017.

[74] T. G. van Erp, I. Guella, M. P. Vawter et al., “Schizophrenia miR-137 locus risk genotype is associated with dorsolateral prefrontal cortex hyperactivation,” Biological Psychiatry, vol. 75, no. 5, pp. 398–405, 2014.

[75] E. Cummings, G. Donohoe, A. Hargreaves et al., “Mood congruent psychotic symptoms and specific cognitive deficits in carriers of the novel schizophrenia risk variant at miR-137,” Neuroscience Letters, vol. 532, pp. 33–38, 2013.

[76] X. Pu and X. Xiao, “No evidence of an association between miR137 rs1625579 and schizophrenia in Asians: a meta-analysis in 30 843 individuals,” Psychiatric Genetics, vol. 26, no. 5, pp. 203–210, 2016.

[77] M. D. Ozel, M. E. Onder, and A. Szazci, “Transcription factor 4 gene rs9960767 polymorphism in bipolar disorder,” Biomedical Reports, vol. 5, no. 4, pp. 506–510, 2016.

[78] J.-Y. Gao, P. Ma, Y. Li et al., “Association between aTCF4Polymorphism and susceptibility to schizophrenia,” BioMed Research International, vol. 2020, Article ID 1216303, 6 pages, 2020.

[79] L. Hui, W. W. Rao, Q. Yu et al., “TCF4 gene polymorphism is associated with cognition in patients with schizophrenia and healthy controls,” Journal of Psychiatric Research, vol. 69, pp. 95–101, 2015.

[80] P. Gasso, V. Sanchez-Gistau, S. Mas et al., “Association of CACNA1C and SYNE1 in offspring of patients with psychiatric disorders,” Psychiatry Research, vol. 245, pp. 427–435, 2016.